[Comment] When Alzheimer's disease prevention becomes policy: regulatory speed, commercialisation, and risk

As Alzheimer's disease research focuses on earlier and asymptomatic stages, and as biomarker technologies advance, attention has turned to the feasibility of preventing cognitive impairment rather than treating established dementia. In their Policy View,1 Eric Reiman and colleagues argue that the Alzheimer's disease research, regulatory, and care community, including investigators, regulators, payers, industry, and health systems, should urgently prepare for the imminent prevention of clinical Alzheimer's disease.